ImmunoGen, Inc. Announces Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference
CAMBRIDGE, Mass., Dec 27, 2007 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) is scheduled to present at the 26th Annual JPMorgan Healthcare Conference at 12:00 noon PST on January 10, 2008 at the Westin St. Francis Hotel in San Francisco, CA. The presentation will be webcast live and can be accessed through the "Investor Relations" section of the ImmunoGen website, www.immunogen.com. An archive of the webcast will be available at the same location until January 17, 2008.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - IMGN901 and IMGN242. Three TAP compounds are in clinical testing through ImmunoGen's collaborations with other companies - AVE9633 and SAR3419, in development by sanofi-aventis, and T-DM1 (trastuzumab-DM1), in development by Genentech. Additionally, the naked antibody compound, AVE1642, is in clinical testing through the Company's collaboration with sanofi-aventis. Multiple compounds are in research/preclinical development through ImmunoGen's collaborations and internal programs.
Investors
ImmunoGen, Inc.
Carol Hausner, 617-995-2500
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
